Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

Development of an Active Heat Dissipation Device Based on Thermoelectric Cooling Technology: Aiming to Improve Endurance Sports Performance

NCT07539714 · tracked via the Priya Life Science Taiwan tracker
Phase
Not applicable
Started
2026-02-01
Last updated
2026-04-20

Condition(s) studied

Heat Stroke

Investigational drug(s) / intervention(s)

TEC VestNo Pre-Cooling (Without Vest)Water Cooled Vest

TEC Vest: Intervention 1: Active Pre-Cooling Vest Type: Device (active cooling garment) Timing: 30 minutes before exercise (pre-cooling period) Procedure: Participants wear the temperature-controlled vest in a hot/humid lab setting before the endurance aerobic exercise test. Purpose: Reduce thermal strain and cardiovascular load; improve comfort; modulate peripheral circulation responses.

No Pre-Cooling (Without Vest): Intervention 2: No Pre-Cooling Without Vest Type: No intervention / usual condition Timing: 30 min Duration Procedure: Participants rest quietly for the same pre-exercise duration without wearing a cooling vest, then complete the identical warm-up and exercise protocol.

Water Cooled Vest: Type: Device (active cooling garment) Timing: 30 minutes before exercise (pre-cooling period) Procedure: Participants wear the water cooled vest in a hot/humid lab setting before the endurance aerobic exercise test. Purpose: Reduce thermal strain and cardiovascular load; improve comfort; modulate peripheral circulation responses.

Study summary

This project investigates the effectiveness of pre-exercise active cooling using a temperature-controlled cooling vest in reducing heat-related physiological strain during endurance-type aerobic exercise in non-regularly trained ("weekend") athletes under hot and humid environmental conditions. Because these individuals often lack sufficient heat-acclimation training, they are at increased risk of excessive thermal stress, cardiovascular overload, and heat-related disorders during prolonged exercise.

Using a controlled laboratory design, participants will perform moderate-intensity endurance exercise in a simulated hot environment, with or without pre-cooling intervention. Peripheral circulation and thermoregulatory responses will be assessed through laser Doppler flowmetry based skin blood-flow analysis and infrared thermography, alongside heart rate and perceived exertion measures.

The study aims to clarify how active pre-cooling influences vascular regulation, sympathetic activity, skin temperature distribution, and exercise tolerance, and to evaluate its potential as a practical, non-fatiguing alternative to heat-acclimation training. The findings are expected to provide evidence-based guidance for reducing heat strain and improving exercise safety and comfort in recreational endurance athletes exercising in hot climates.

Eligibility

Sex
ALL
Min age
20 Years
Max age
50 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Age 20-50 years. * In the past 6 months, endurance exercise less than three times per week, 40-60 min each session. * No cardiovascular, metabolic (e.g., diabetes), or neurological disorders, and no diseases affecting vascular regulation. * No medication affecting vascular tone within the last 3 months. * No major musculoskeletal injuries or disorders affecting performance within the last 3 months. Exclusion Criteria: * • Diabetes, hypertension, or peripheral vascular disease. * Long-term work in hot environments. * BMI \> 30 kg/m², smoking, or heavy alcohol use. * Allergic reactions triggered by heat or cold (e.g., hives).

Primary outcome measure(s)

  • Heart Rate — During a single laboratory visit lasting approx. 40 minutes: baseline immediately before the pre cooling period,immediately after 30 minutes of pre cooling,immediately after the 5 minute exercise bout, and immediately after the 5 minute seated cool down.
  • Temperature — During a single laboratory visit lasting approx.40 minutes: baseline immediately before the pre cooling period, immediately after 30 minutes of pre cooling,immediately after the 5 minute exercise bout, and immediately after the 5 minute seated cool down.

Trial sites (1)

FacilityCityRegionStatus
Cooling Vest Kaohsiung City Sanmin
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07539714 on ClinicalTrials.gov ↗ ← All trials in Taiwan